For an undisclosed sum, Germany’s Evonik has acquired German industrial biotech JeNaCell, thereby expanding its biomaterials portfolio to biotechnologically derived cellulose. The Essen-based group said the acquisition confirms its venture capital arm’s strategy of investing early in start-ups with visionary technology relevant to its own innovation growth fields.
Evonik has entered into an agreement to buy Infinitec Activos, a privately owned Spanish company that specializes in the development and production of novel delivery systems for cosmetic active ingredients. Financial terms were not disclosed.
German specialty chemicals producer Evonik delivered the first batches of lipids for BioNTech’s mRNA-based Covid-19 vaccine on Apr. 22, months earlier than planned. Deliveries were expected to start in mid-2021 but the company said it was able to set up production in just eight weeks at its complex in Hanau, Germany, and meet the high-quality requirements for the component.
The European Chemical Industry has set out on an ambitious path to become carbon neutral. Germany, as one of the major chemical manufacturing nations, has committed to achieve this goal by 2050.
Japan’s Ajinomoto has entered into exclusive negotiations with French fermentation firm METabolic EXplorer to sell its entire stake in Ajinomoto Animal Nutrition Europe (AANE), based in Amiens, France. The company said the sale its part of a strategic reshaping of its portfolio and a restructuring of non-core businesses.
Seven companies from the European GET H2 hydrogen initiative, including chemical producer Evonik, have established a consortium to help promote industrial offtake of climate-friendly green hydrogen from renewable energies.
Michael Reubold talked to Evonik’s Sanjeev Taneja about the role of catalysts in the company and their value to the industry and the society.
The European Chemical Industry has set out on an ambitious path to become carbon neutral.
Evonik has entered into an agreement to buy the Lactel absorbable polymer business from Durect Corp., a US-based biopharmaceutical company focused on developing drugs for pain and chronic diseases.
German specialty chemicals producer Evonik says it is on track to complete the ongoing €400 million expansion of its PA 12 portfolio as planned, despite a few logistical challenges related to the coronavirus pandemic.
Evonik and Siemens Energy have commissioned a pilot plant that uses carbon dioxide (CO2) and water to produce chemicals. The plant is the culmination of two years’ work under the Rheticus I and II research projects to develop a technically feasible foundation for artificial photosynthesis using a bioreactor and electrolyzers.
The pharmaceutical industry is increasingly focused on the development of specialized drug products with new treatment modalities, including previously undruggable targets for oncology and other areas.
Specialty chemicals producer Evonik is investing around €15 million in its C4 production network in Marl. Germany. The three-pronged focus is on Tert. butanol (TBA), di-isobutene (DiB) and 3,5,5-trimethylhexanal (TMH).
In a move designed to boost its catalyst business, Evonik will pay $210 million to acquire the Porocel Group, a US technology provider based in Houston, Texas. The transaction, to be financed out of Evonik's “strong cash position,” is due to close by the end of 2020 subject to regulatory approval.
The chemical industry is on the threshold of a new era – the age of circularity. We asked industry experts to share their opinions on this transformational topic.
The fate of the agrochemical innovation, development, product launch and production are strongly linked to the parallel development of the fine chemicals and custom manufacturing industry.
With the transfer of Evonik’s methacrylates business to private equity investor Advent International, Röhm, one of the world’s leading producers of methyl methacrylate (MMA) monomer and PMMA molding compounds, is now called Röhm again. The company based at Darmstadt, Germany, also has a new logo.
